Parameters | Base value | Distribution | Range | Source | |
---|---|---|---|---|---|
Drug costs ($) | |||||
Sintilimab (100 mg) | 166.92 | Gamma | 133.54-166.92 | [20] | |
Bevacizumab biosimilar (100 mg) | 177.13 | Gamma | 123.99-177.13 | [20] | |
Lenvatinib (4 mg) | 16.69 | Gamma | 11.68–16.69 | [20] | |
Subsequent treatment ($) | |||||
Sintilimab + Bevacizumab | 442.29 | Gamma | 353.83-530.74 | [6] | |
Lenvatinib | 631.81 | Gamma | 505.45-758.17 | [6] | |
End-of-life care ($) | 2132.67 | Gamma | 888.10-6108.44 | [21] | |
Cost of follow-up per visit ($) | |||||
Computer tomography | 90.43 | Gamma | 64.91-146.83 | Medical service price database of 11 provinces in China | |
Blood biochemistry | 24.27 | Gamma | 13.76–38.02 | ||
Blood routine | 1.58 | Gamma | 0.77–2.94 | ||
Urine routine | 0.67 | Gamma | 0.15–1.39 | ||
Myocardial enzyme test | 5.13 | Gamma | 3.09–7.73 | ||
alpha feprotein test | 3.18 | Gamma | 2.16–4.64 | ||
Cost of drug administration ($) | |||||
Diagnosis | 5.13 | Gamma | 3.09–7.73 | Medical service price database of 11 provinces in China | |
Intravenous injection | 1.73 | Gamma | 0.46–4.64 | ||
Nursing | 1.27 | Gamma | 0.77–1.85 | ||
Bed | 2.05 | Gamma | 1.64–2.47 | ||
Cost of AEs per event ($) | |||||
Hypertension | 3.42 | Gamma | 2.73–4.10 | Expert opinion | |
Proteinuria | 22.10 | Gamma | 17.68–26.52 | Expert opinion | |
Platelet count decreased | 176.55 | Gamma | 141.24-211.86 | Expert opinion | |
Elevated bilirubin | 77.28 | Gamma | 61.82–92.74 | Expert opinion | |
Elevated aspartate aminotransferase | 77.28 | Gamma | 61.82–92.74 | Expert opinion | |
HR (Sintilimab + Bevacizumab versus Lenvatinib) | |||||
PFS | 0.856 | Log-normal | 0.798–0.910 | ||
OS | 0.618 | Log-normal | 0.546–0.708 | ||
Probability of AEs (per cycle)* | |||||
Sintilimab + Bevacizumab | |||||
Hypertension | 0.72% | Beta | 0.58-0.87% | [6] | |
Platelet count decreased | 0.33% | Beta | 0.27-0.40% | [6] | |
Lenvatinib | |||||
Hypertension | 1.32% | Beta | 1.06-1.58% | [9] | |
Proteinuria | 0.35% | Beta | 0.28-0.41% | [9] | |
Platelet count decreased | 0.29% | Beta | 0.23-0.35% | [9] | |
Elevated bilirubin | 0.40% | Beta | 0.32-0.48% | [9] | |
Elevated aspartate aminotransferase | 0.29% | Beta | 0.23-0.35% | [9] | |
Health state utility | |||||
PFS state | 0.745 | Beta | 0.730–0.760 | [17] | |
PP state | 0.678 | Beta | 0.655–0.701 | [17] | |
Disutility of AEs | |||||
Hypertension | -0.12 | Beta | -0.10 to -0.14 | [18] | |
Proteinuria | -0.12 | Beta | -0.10 to -0.14 | [18] | |
Decreased platelet count | 0.00 | Beta | 0.00 | [19] | |
Increased blood bilirubin | 0.00 | Beta | 0.00 | [19] | |
Elevated aspartate aminotransferase | 0.00 | Beta | 0.00 | [19] | |
Discount rate (per cycle) | 0.28% | Beta | 0.00-0.44% |